Dr Deborah Pritchard and Dr Gwen Wark, members of the UK NEQAS Board, explain how UK NEQAS gives users the confidence that they are providing the best results for their assays, and clinical teams and patients the reassurance that they are receiving the correct information to manage health conditions and treatment.
Everything that UK NEQAS does is for the benefit of patients. All the impartial advice delivered, the challenging samples sent to laboratories, the webinars and conferences hosted, and the data shared – everything is done to try to improve the potential outcomes of the patients.
With 70% of diagnoses relying on pathology results, patients are the reason why EQA exists and why it’s imperative that we always keep them in mind when delivering EQA. These are real people, going through a very challenging time in their lives, and despite us not being physically alongside them, our work impacts their treatment and prognosis. We have to ensure that every single test result is right the first time.
Some 8000 biochemistry samples are analysed on average, every day in just one hospital – that means thousands of patients are relying on the outcome of laboratory tests either for diagnosing a new condition or for monitoring chronic disease. It puts the importance of EQA into sharp focus.
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.